107754-55-2

Basic information

• Product Name: methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate
• Synonyms: methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate
• CAS NO: 107754-55-2
• Molecular Weight: 341.323
• Mol File: 107754-55-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate(107754-55-2)
• EPA Substance Registry System: methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate(107754-55-2)

Safety Data

• Hazardous Substances Data: 107754-55-2(Hazardous Substances Data)

Upstream product

• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 94-52-0 6-nitro-1H-benzo[d]imidazole 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 
• 94-52-0 5-nitrobenzimidazole 

Downstream Products

• 107754-54-1 methyl 4-<(6-aminobenzimidazol-1-yl)methyl>-3-methoxybenzoate 
• 107786-78-7 N-<4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoyl>benzenesulfonamide 
• 107786-77-6 N-[4-[6-(2-cyclopentylacetamido)benzimidazol-1-ylmethyl]-3-methoxybenzoyl]-benzenesulphonamide 
• 107754-53-0 methyl 4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoate 
• 107786-75-4 methyl 4-<<6-(2-cyclopentylacetamido)benzimidazol-1-yl>methyl>-3-methoxybenzoate 
• 107754-56-3 4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoic acid 
• 107786-76-5 4-<<6-(2-cyclopentylacetamido)benzimidazol-1-yl>methyl>-3-methoxybenzoic acid 

Relevant articles and documents

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.

Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

The dissociation constants (K(B)) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurathane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The K(B) was found to be remarkably toler